Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Clear-Cell Renal Cell Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00001703
What this trial is testing

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
National Cancer Institute (NCI) 6
Testing effectiveness (Phase 2)Study completedNCT00787761
What this trial is testing

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Who this might be right for
Myeloproliferative DisordersKidney CancerLeukemia+4 more
Northside Hospital, Inc. 24
Not applicableStudy completedNCT05745142
What this trial is testing

Go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

Who this might be right for
Carcinoma, Renal CellClear-cell Metastatic Renal Cell Carcinoma
Pfizer 376
Early research (Phase 1)Study completedNCT01772004
What this trial is testing

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Who this might be right for
Solid Tumors
EMD Serono Research & Development Institute, Inc. 1,756
Testing effectiveness (Phase 2)Study completedNCT03013335
What this trial is testing

Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

Who this might be right for
Metastatic Renal Cell Carcinoma
UNICANCER 730
Early research (Phase 1)Study completedNCT01588678
What this trial is testing

A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

Who this might be right for
Advanced Solid TumorLymphoma
Daiichi Sankyo 32
Testing effectiveness (Phase 2)Looking for participantsNCT07187778
What this trial is testing

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

Who this might be right for
Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center 10
Not applicableActive Not RecruitingNCT03647878
What this trial is testing

Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.

Who this might be right for
Advanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
Ipsen 224
Testing effectiveness (Phase 2)Looking for participantsNCT05817903
What this trial is testing

Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Who this might be right for
Metastatic Renal Cell Carcinoma
Consorzio Oncotech 118
Not applicableStudy completedNCT04353765
What this trial is testing

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Who this might be right for
Locally Advanced or Metastatic Renal Cell Carcinoma
Ipsen 247
Early research (Phase 1)Active Not RecruitingNCT04606472
What this trial is testing

SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 60
Testing effectiveness (Phase 2)Looking for participantsNCT05155033
What this trial is testing

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Who this might be right for
Metastatic MelanomaAdvanced Locoregional MelanomaMetastatic Renal Cell Carcinoma+1 more
National Cancer Institute (NCI) 78
Not applicableLooking for participantsNCT07166445
What this trial is testing

Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT

Who this might be right for
Carcinoma, Renal CellDiagnostic ImagingPathology+1 more
Peking University First Hospital 1,000
Testing effectiveness (Phase 2)Ended earlyNCT01727336
What this trial is testing

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

Who this might be right for
Advanced Renal Cell Carcinoma
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 160
Testing effectiveness (Phase 2)UnknownNCT04644432
What this trial is testing

Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

Who this might be right for
Metastatic Renal Cell CarcinomaKidney NeoplasmUrologic Neoplasms+1 more
Herlev and Gentofte Hospital 30
Early research (Phase 1)Study completedNCT01472081
What this trial is testing

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Who this might be right for
Renal Cell CarcinomaClear-cell Metastatic Renal Cell Carcinoma
Bristol-Myers Squibb 194
Testing effectiveness (Phase 2)Looking for participantsNCT06682793
What this trial is testing

Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more
A2 Biotherapeutics Inc. 240
Post-approval studies (Phase 4)Ended earlyNCT00930345
What this trial is testing

Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Who this might be right for
Metastatic Renal Cell Carcinoma
Assistance Publique - Hôpitaux de Paris 33
Not applicableStudy completedNCT00831857
What this trial is testing

VEGF Imaging in Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
University Medical Center Groningen 26
Testing effectiveness (Phase 2)Study completedNCT03354884
What this trial is testing

CaBozantinib in cOllectiNg ductS Renal Cell cArcInoma

Who this might be right for
Collecting Duct Carcinoma (Kidney)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 23
Next Page